Among 1687 patients treated with BMS who were randomized to continued thienopyridine vs placebo , rates of stent thrombosis were 0.5 % vs 1.11 % ( n = 4 vs 9 ; hazard ratio [ HR ] , 0.49 ; 95 % CI , 0.15-1 .64 ; P = .24 ) , rates of MACCE were 4.04 % vs 4.69 % ( n = 33 vs 38 ; HR , 0.92 ; 95 % CI , 0.57-1 .47 ; P = .72 ) , and rates of moderate/severe bleeding were 2.03 % vs 0.90 % ( n = 16 vs 7 ; P = .07 ) , respectively .